About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 3NCT00263640

Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma

The trial is performed to assess efficacy and safety of the Allergopharma house dust mite allergoid in bronchial asthma.

Lead sponsor: Allergopharma GmbH & Co. KG•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Allergopharma GmbH & Co. KG

The rationale for the present study was to demonstrate clinical efficacy and tolerability compared to placebo in a phase III clinical study of pivotal character with a representative number of patients suffering from fully reversible asthma +/- allergic rhinitis. This condition is present in paediatric and adult patients with a shorter history of GINA II and III asthma, who were investigated in this study.

Age

6 - 40 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Bronchial asthma
•Requirements for inhaled corticosteroid
•Positive skin prick test to house dust mite
•Positive radioallergosorbent test (RAST) to house dust mite
•Positive provocation test result to house dust mite

Exclusion Criteria

•Serious chronic diseases
•Other perennial allergies

Related studies

COMPLETEDPhase 2

Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)

NCT03688074 · Asthma, Bronchial Diseases, and more

Asthma Data Innovation Demonstration Project

NCT02162576 · Asthma, Bronchial Diseases, and more

Ai Chi Method for Children With Asthma

NCT03392129 · Asthma, Child, and more

COMPLETEDPhase 3

Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent Asthma

NCT00254956 · Respiratory Tract Diseases, Respiratory Hypersensitivity, and more

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 15, 2015Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment130

Start dateMay 2005

Last updatedJan 15, 2015

Condition

Respiratory Hypersensitivity

Locations shown

Allergopharma GmbH & Co. KG

Reinbek

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 15, 2015Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions